Aurobindo Pharma gains 5%, hits 52-week high as Q4 net profit jumps 45% YoY

That apart, the company informed the exchanges that the US FDA has classified the inspection of the company's oral solids formulation manufacturing facility at New Jersey as Official Action Indicated

Shares of Aurobindo Pharma surged 5 per cent and hit a 52-week high of Rs 791 on the BSE on Thursday in the early morning deals after the company reported healthy March quarter results. That apart, early today, the company informed the exchanges that the US Food and Drug Administration (FDA) has classified the inspection of the company's oral solids formulation manufacturing facility at New Jersey as official action indicated (OAI).

On Wednesday, the drug maker reported a 32 per cent jump in profit before tax (PBT) at Rs 1,077.51 crore for the quarter ended March 31, 2020 as compared to